|Enanta Pharmaceuticals, Inc.|
500 Arsenal Street
United States - Map
Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. Its lead product is paritaprevir, a protease inhibitor designed for use against the hepatitis C virus (HCV). The company also develops HCV protease inhibitor in phase III development with AbbVie, as well as a HCV program using a different class of molecules known as cyclophilin inhibitors. In addition, it has a program in non-alcoholic steatohepatitis; and discovers programs in other areas of viral infection and liver disease. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with AbbVie to develop and commercialize HCV NS3 and NS3/4A protease inhibitors. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
|Enanta Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Feb 1, 2016 is 6. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 8; Compensation: 5.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Dr. Jay R. Luly Ph.D.,
Chief Exec. Officer, Pres and Director
|Mr. Paul J. Mellett Jr.,
Chief Financial Officer and Sr. VP of Fin. & Admin.
|Dr. Yat Sun Or Ph.D.,
Chief Scientific Officer and Sr. VP of R&D
|Mr. Nathaniel S. Gardiner J.D.,
Sr. VP, Gen. Counsel and Sec.
|Dr. Timothy D. Ocain Ph.D.,
Sr. VP of New Product Strategy and Devel.
|Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|